Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1231 to 1245 of 1257 results for pathway

  1. Two technologies to provide digital services for people with COPD

    More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.

  2. NICE and NHS England announce plan to enable innovative tech to be adopted quicker

    NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.

  3. Help shape our new service: Understanding regulations of AI and digital technology in health and social care

    As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.

  4. A refreshed Evidence Standards Framework for Digital Health Technologies

    Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.

  5. How is NICE supporting digital health technology developers?

    Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.

  6. Over 500 people a year can access a new life extending lung cancer treatment

    An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.

  7. Two new treatment options for incurable blood cancer assessed

    We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.

  8. NICE is gearing up for the evaluation of further digital health technologies as pilot project produces first result

    Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.

  9. New LSE master's degree in Evaluation of Health Care Interventions and Outcomes

    NICE is collaborating with the London School of Economics and Political Science (LSE) to develop an executive master’s degree in health care decision-making.

  10. New treatment for cardiovascular disease could benefit millions

    Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.

  11. NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation

    NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).

  12. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund

    A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.

  13. Supporting innovation: clear approval pathways and evidence standards for AI-driven digital health technologies

    Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.

  14. Starting with the end in mind - the Innovative Licensing and Access Pathway

    The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.

  15. More evidence needed to recommend Type 2 diabetes treatment tirzepatide

    More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use